Northeast Pharmaceutical Group Co., Ltd. (000597.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 4.65

From 52W high−16.72%

Volume9.87M

Market capCNY 6.96B

P/E (TTM)26.8x

P/S (TTM)0.9x

Div yield1.18%

Key dataSep 18, 2026

Open

CNY 4.65

From 52W high

−16.72%

Volume

9.87M

Market cap

CNY 6.96B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

5.8x

P/E (TTM)

26.8x

RSI (14)

42.6

MomentumView details →

1D Return

−2.59%

YTD Return

−10.73%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

26.8x

EV/EBITDA

5.8x

EV/Sales

0.7x

P/S (TTM)

0.9x

P/B (TTM)

1.3x

ProfitabilityView details →

Gross Margin

35.65%

Net Margin

3.51%

EBITDA Margin

11.76%

ROE (TTM)

4.51%

ROA (TTM)

1.84%

Asset Turnover

0.54x

GrowthView details →

Revenue YoY

−5.00%

EPS YoY

−36.73%

FCF YoY

+114.28%

Revenue CAGR 3Y

−7.05%

EPS CAGR 3Y

−10.37%

EBITDA YoY

—

MomentumView details →

1D Return

−2.59%

YTD Return

−10.73%

1Y Return

−15.27%

RSI (14)

42.6

vs 50D SMA

−3.04%

vs 200D SMA

−7.04%

Capital & dividendView details →

Debt/Equity

0.33x

Current Ratio

1.15x

Quick Ratio

0.98x

Div Yield

1.18%

Div Rate

CNY 0.06

Div Growth 1Y

−45.00%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

7.13B

Net Income (TTM)

250.38M

Op. CF (TTM)

1.15B

Latest newsMore news →

Northeast Pharmaceutical's wholly owned subsidiary Northeast Pharmaceutical Group Shenyang First Pharmaceutical received approval from the National Medical Products Administration for a supplementary drug application for Efavirenz Tablets, adding a 0.2g specification with drug approval number H20269225 valid until March 22, 2031.6d ago

On September 1, 2026, after market close, 12 A-share listed companies including Yiatong, Henggong Precision, Weihong, Jiuzhou Yigui, Zhongman Petroleum, Shanghai Xiba, Gongdong Medical, Jincang Group, Northeast Pharmaceutical, Kingmed Diagnostics, Yongzhen, and Fuchun Dyeing disclosed plans to reduce holdings, while Huaxia Eye Hospital disclosed a plan to increase holdings.20d ago

Similar companies

德尔未来002631.SZ 亚太股份002284.SZ 纳百川301667.SZ 光韵达300227.SZ 利民股份002734.SZ 华源控股002787.SZ Find similar companies →

Latest newsMore news →

Northeast Pharmaceutical's wholly owned subsidiary Northeast Pharmaceutical Group Shenyang First Pharmaceutical received approval from the National Medical Products Administration for a supplementary drug application for Efavirenz Tablets, adding a 0.2g specification with drug approval number H20269225 valid until March 22, 2031.6d ago On September 1, 2026, after market close, 12 A-share listed companies including Yiatong, Henggong Precision, Weihong, Jiuzhou Yigui, Zhongman Petroleum, Shanghai Xiba, Gongdong Medical, Jincang Group, Northeast Pharmaceutical, Kingmed Diagnostics, Yongzhen, and Fuchun Dyeing disclosed plans to reduce holdings, while Huaxia Eye Hospital disclosed a plan to increase holdings.20d ago Northeast Pharmaceutical director Guo Jianmin plans to sell up to 0.0560% of the company's shares within three months starting 15 trading days after September 2, 2026.20d ago